The Valley Desk

ArticleThe Lancet. RheumatologyPublished

Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2b, dose-ranging study

Read the publication ↗

Regional connection

Verified An author affiliation on the Europe PMC record names GSK. Affiliation source

Institution
GSK

Publication record

Type
Article
Venue
The Lancet. Rheumatology
Published
PubMed ID
38279364
Added to directory
Source checked

Report a correction or request removal